Recursion delivered a genome‑scale microglia phenomap to Roche/Genentech as part of their multi‑year AI discovery collaboration, triggering a $30 million milestone payment. The dataset—millions of microglial cell images and perturbation profiles—aims to reveal new neurodegenerative targets and accelerate drug discovery across neuroscience indications. The transfer marks another example of AI‑first firms packaging large“phenomaps” for pharma partners, converting image‑based high‑content screening into target hypotheses. Recursion called the map a foundational deliverable for multiple neuroscience programs and said it will continue to develop complementary phenomaps for other therapeutic areas.